CFU-Mk Content of Immunoselected CD34 + Peripheral Blood Progenitor Cells,Evaluated with an Adapted Serum-Free Methylcellulose Assay,Is Predictive of Platelet Lineage Reconstitution in Children with Solid Tumors

Abstract

Immunoselected CD34⁺ peripheral blood progenitor cell (PBPC) transplantation is now frequently used to support autologous hematopoiesis after myeloablative therapy, its feasability having been proved by several groups. However, we and others observed delayed platelet recovery. We hypothesized that immunoselection processing might induce selective loss of megakaryocyte progenitors, or a decrease in their proliferation. We used a colony-forming units megakaryocyte (CFU-Mk) assay to evaluate these consequences and predict platelet recovery in patients. In CD34⁺ PBPCs from 10 children with solid tumors, we observed no selective loss in CFU-Mk numbers during immunoselection processing and no impairment of clonogenicity. The CFU-Mk yield (59.2 plusmn; 11.3%) was at least similar to the CD34⁺ yield (44.2 ± 3.8%). We assessed the predictive value of CFU-Mk numbers infused for recovery of platelet lineage. We found an inverse correlation between the time taken to reach a platelet count greater than 50 X 10⁹/L and only the CFU-Mk dose (r = -0.71; p = 0.022) among the different type of progenitors, including colony-forming units granulocytemacrophage (CFU-GM), burst-forming units erythrocyte (BFU-E) and colony-forming units-mixed (CFU-Mix). These findings suggest that CFU-Mk number could be used as sole predictive functional parameter for platelet reconstitution in children after immunoselection of CD34⁺ cells, in particular for low CD34⁺ cell dose, and thus as an indicator for initial quality of hematopoietic cells before in vitro expansion.